suz12b Antibody

What is SUZ12 and what is its cellular function?

SUZ12 is a key component of the Polycomb Repressive Complex 2/3/4 (PRC2/3/4), which plays critical roles in embryonic development through epigenetic silencing of target genes. SUZ12 functions primarily as a transcriptional repressor through its association with the histone methyltransferase Ezh2, which methylates histone H3 at lysine 27 (H3me3K27) . ChIP-chip studies have demonstrated that SUZ12 binds to silenced regions of the genome in a cell-type specific manner, with less than 1% of SUZ12 target promoters showing RNA Polymerase II occupancy, confirming its repressive role . In embryonic cells, SUZ12 predominantly targets transcription factors and homeobox proteins, while in adult tumors it targets glycoproteins, receptors, and immunoglobulin-related genes .

What applications can SUZ12 antibodies be used for?

SUZ12 antibodies have been validated for multiple experimental applications including:

SUZ12 antibodies have been successfully employed in key research applications including genome-wide binding site identification and co-localization studies with other PRC complex components .

How should SUZ12 antibodies be stored and handled?

Proper storage and handling of SUZ12 antibodies is essential for maintaining their activity and specificity. Most SUZ12 antibodies can be stored at 4°C for up to three months for ongoing experiments . For long-term storage, -20°C is recommended, where the antibody remains stable for up to one year .

SUZ12 antibodies are typically supplied in PBS containing preservatives such as 0.02% sodium azide and sometimes with 50% glycerol at pH 7.3 . Smaller volumes (e.g., 20μl sizes) often contain 0.1% BSA as a stabilizer, making aliquoting unnecessary for -20°C storage in some cases . To maintain antibody integrity, avoid repeated freeze-thaw cycles, keep on ice during use, and return to appropriate storage promptly after experimentation.

What is the molecular weight of SUZ12 protein?

In specific applications, such as detection in JEG-3 human epithelial choriocarcinoma cell line, SUZ12 appears as a specific band at approximately 90 kDa when using antibodies like MAB4184 . The consistency of this molecular weight observation across multiple cell lines and antibodies provides a reliable marker for verifying detection specificity.

How does SUZ12 binding pattern differ between embryonic and adult tumor cells?

ChIP-chip studies have revealed striking differences in SUZ12 binding patterns between embryonic and adult tumor cells:

This cell-type specificity suggests that SUZ12 plays distinct roles in embryonic development versus adult tumor progression . The binding patterns likely reflect the different gene expression programs requiring regulation in these cellular contexts. These findings emphasize the importance of studying SUZ12 function in the specific cell type of interest rather than extrapolating findings across different systems .

What is the relationship between SUZ12 binding and histone modifications?

SUZ12 binding shows a remarkably strong correlation with specific histone modifications, particularly trimethylation of lysine 27 on histone H3 (H3me3K27). ChIP-chip experiments in F9 cells revealed that approximately 88% of SUZ12 target promoters are also in the top 2000 promoters detected by H3me3K27 antibody . In contrast, only 3% of SUZ12 target promoters are found in the top 2000 promoters detected by H3me3K9 antibody .

This strong association with H3me3K27 but not H3me3K9 is consistent with the known function of the PRC2/3/4 complex, which includes Ezh2, a histone methyltransferase that specifically methylates H3K27 . The presence of H3me3K27 at SUZ12-bound regions supports the role of SUZ12 in transcriptional repression, as H3me3K27 is a well-established repressive histone mark. This tight correlation can be used as a validation approach when identifying SUZ12 target genes through ChIP experiments.

How can I optimize ChIP-chip/ChIP-seq protocols for SUZ12 antibodies?

Optimizing ChIP-chip/ChIP-seq protocols for SUZ12 antibodies requires careful attention to several key aspects:

• Antibody selection: Use antibodies specifically validated for ChIP applications, such as those that have been demonstrated to enrich for known SUZ12 targets .

• Cross-linking and chromatin preparation: Standard formaldehyde treatment (1% for 10 minutes at room temperature) is typically effective for SUZ12. Ensure optimal chromatin fragmentation to 200-500bp fragments.

• Immunoprecipitation conditions: Use 4-10 μg of antibody per reaction, and include appropriate positive controls (known SUZ12 targets like Wnt1) and negative controls (promoters not bound by SUZ12, such as RNAPII) .

• Validation strategy: Perform at least two independent biological replicates. Research has shown that the overlap between replicates increases sharply for the top 2000 ranked promoters, providing a non-arbitrary method for identifying robust target sets .

• Confirmatory analysis: PCR validation of selected targets from different ranks in your ChIP-chip dataset is recommended. Compare your SUZ12 binding data with H3me3K27 ChIP-chip data, as there should be significant overlap (approximately 88%) .

What controls should I use when conducting SUZ12 immunoprecipitation?

When conducting SUZ12 immunoprecipitation, several controls are essential to ensure specificity and reliability:

• Negative controls:

  • No-antibody or IgG control to account for non-specific binding

  • RNAPII promoter has been shown not to associate with SUZ12

  • SUZ12 knockout/knockdown samples where available

• Positive controls:

  • Known SUZ12 interacting proteins

  • Known SUZ12 target gene promoters (such as Wnt1 in mouse cells)

• Validation controls:

  • For co-immunoprecipitation, perform the IP in reverse (IP with antibodies against the potential interacting partner and blot for SUZ12)

  • Parallel ChIPs with antibodies against other PRC complex components (like Ezh2) and H3me3K27

  • For IP-Western validation, use a secondary antibody against SUZ12 from a different host species or targeting a different epitope, as demonstrated with mouse monoclonal SUZ12 antibody for IP and sheep polyclonal SUZ12 antibody for detection

What are the optimal antibody dilutions for different applications of SUZ12 antibodies?

The optimal antibody dilution varies significantly depending on the specific SUZ12 antibody and application:

These recommendations provide starting points, but optimization for your specific experimental conditions, antibody lot, and sample type is crucial . Perform a dilution series to determine the optimal concentration that provides the best signal-to-noise ratio for your particular application.

How should I validate SUZ12 antibody specificity in my experiments?

Validating SUZ12 antibody specificity requires a multi-faceted approach:

• Western blot validation: Use positive control lysates from cells known to express SUZ12 (HeLa, HepG2, MCF-7, or JEG-3 cells) and verify a single band at 80-90 kDa . Compare with negative controls such as SUZ12 knockdown cells.

• Localization pattern: Verify nuclear localization in microscopy applications, as SUZ12 is predominantly a nuclear protein. In D3 mouse embryonic stem cells, SUZ12 shows specific nuclear staining that can be visualized using secondary antibodies like NorthernLights 557-conjugated Anti-Mouse IgG and DAPI counterstaining .

• Chromatin-association validation: Perform western blotting on nuclear versus cytoplasmic fractions. Analysis in JEG-3 cells shows SUZ12 predominantly in the nuclear fraction .

• Cross-validation: Use multiple antibodies targeting different epitopes of SUZ12. Concordant results strengthen confidence in specificity.

• Functional validation: Verify co-localization with other PRC2 complex components and association with H3me3K27 but not H3me3K9 histone marks .

• ChIP-qPCR validation: Test enrichment at known SUZ12 target genes versus non-target genes using qPCR analysis of immunoprecipitated DNA .

What antigen retrieval methods work best for SUZ12 immunohistochemistry?

For optimal SUZ12 detection in immunohistochemistry, heat-induced epitope retrieval (HIER) methods have proven most effective:

• Primary recommended method: TE buffer at pH 9.0 . This alkaline pH helps break protein cross-links formed during fixation and unmasks SUZ12 epitopes.

• Alternative method: Citrate buffer at pH 6.0, though it may yield lower signal intensity for some SUZ12 antibodies .

• Heating protocol: Typically performed using a pressure cooker, microwave, or water bath at 95-100°C for 15-20 minutes, followed by cooling to room temperature.

Specific retrieval conditions may need optimization based on tissue type, fixation method, and the particular SUZ12 antibody. For formalin-fixed paraffin-embedded (FFPE) samples, longer retrieval times may be necessary compared to frozen sections. After antigen retrieval, thorough blocking (3-5% normal serum or BSA) is crucial to minimize background staining.

Validation studies have successfully detected SUZ12 in human tissues such as lung and breast cancer using these methods . Always perform positive control staining on tissues known to express SUZ12 to confirm the effectiveness of your antigen retrieval protocol.

How do I interpret SUZ12 ChIP-chip or ChIP-seq data?

Interpreting SUZ12 ChIP-chip or ChIP-seq data requires specific analytical approaches tailored to its distinctive binding patterns:

• Establish robust peak calling strategy: Research has shown that true SUZ12 targets appear consistently in top-ranked genes across replicate experiments. One validated approach identified SUZ12 targets as promoters ranking in the top 2000 in two independent experiments, yielding 1076 high-confidence targets .

• Validation by qPCR: Validate peaks using qPCR on selected targets spanning a range of enrichment values. Even targets with modest enrichment values (log2 fold change >0.635) have proven to be genuine in follow-up testing .

• Integration with histone modification profiles:

  • H3me3K27: Expect strong overlap (~88%)

  • H3me3K9: Expect minimal overlap (~3%)

• Correlation with transcriptional activity: SUZ12-bound promoters should show minimal overlap (<1%) with RNAPII occupancy, confirming its repressive function .

• Functional enrichment analysis: Perform Gene Ontology analysis to identify functional patterns that should differ based on cell type:

  • Embryonic cells: Transcription factors and homeobox genes

  • Adult tumors: Glycoproteins and immunoglobulin-related genes

• Positional analysis: Note that SUZ12 binding can appear as discrete sites or spread through extended genomic regions .

How can I correlate SUZ12 binding with gene expression data?

Correlating SUZ12 binding with gene expression data requires specific methodological considerations given SUZ12's role as a transcriptional repressor:

• Generate matched datasets: Use ChIP-chip/seq and transcriptome data (RNA-seq or microarray) from the same cell population to ensure direct comparability.

• Categorize by binding intensity: Group genes based on SUZ12 binding intensity (high, medium, low, absent) and compare expression distributions. Expect an inverse relationship where stronger SUZ12 binding correlates with lower expression levels. Published research shows that promoters bound by SUZ12 have minimal overlap (<1%) with RNA Polymerase II occupancy .

• Integrate with histone modification data: The presence of both SUZ12 binding and H3me3K27 provides stronger evidence for active repression than either alone .

• Consider cell type specificity: Analyze cell type-specific binding patterns in relation to tissue-specific gene expression. SUZ12 targets different gene sets in embryonic cells versus adult tumors, suggesting context-dependent regulation .

• Interpretation framework: Remember that absence of SUZ12 binding does not necessarily predict high expression (genes may be repressed by other mechanisms), but presence of SUZ12 binding strongly predicts transcriptional silencing through the associated H3me3K27 modification.

How do I troubleshoot background issues in SUZ12 immunostaining?

High background in SUZ12 immunostaining can be addressed through several methodological adjustments:

• Optimize blocking conditions: Try different blocking agents (BSA, non-fat milk, normal serum from the secondary antibody host species) at various concentrations (3-5%). For SUZ12 antibodies, BSA blocking is often effective and reduces non-specific binding .

• Adjust antibody concentration: Titrate your primary antibody - background often occurs at higher antibody concentrations. For immunohistochemistry, dilutions of 1:200-1:800 are typically recommended .

• Increase wash stringency: Add detergents like Tween-20 (0.1-0.5%) or increase salt concentration in wash buffers to reduce non-specific binding.

• Optimize antigen retrieval: For SUZ12, TE buffer at pH 9.0 is often recommended, though citrate buffer at pH 6.0 can be an alternative . Incomplete antigen retrieval can lead to both weak specific signal and high background.

• Secondary antibody controls: Include a secondary-only control to identify background from the secondary antibody. The NorthernLights 557-conjugated Anti-Mouse IgG Secondary Antibody has been validated for SUZ12 detection with minimal background .

Why might SUZ12 detection vary between different cell types?

SUZ12 detection can vary significantly between cell types due to several factors:

• Expression level differences: SUZ12 is normally expressed at low levels in adult cells but is up-regulated in adult tumors and embryonic cells . This fundamental difference in expression levels affects detection sensitivity.

• Cell type-specific binding patterns: ChIP-chip studies have shown that SUZ12 binding targets differ dramatically between embryonic cells and adult tumor cells . This may affect epitope accessibility in different nuclear environments.

• Complex formation variations: SUZ12 exists within different PRC2/3/4 complexes that may have different compositions across cell types, potentially masking or exposing antibody epitopes.

• Fixation sensitivity: Different cell types may require optimized fixation protocols to preserve SUZ12 antigenicity. Nuclear proteins like SUZ12 can be particularly sensitive to overfixation.

• Subcellular localization: While primarily nuclear, the specific distribution pattern of SUZ12 within the nucleus may vary between cell types. In D3 mouse embryonic stem cells, SUZ12 shows distinct nuclear localization patterns that can be clearly visualized with appropriate immunofluorescence techniques .